Medications That Cause Photosensitive Skin

Introduction to Photosensitive Medications

The American Heart Association recommends that patients taking certain medications, including tetracyclines, thiazide diuretics, fluoroquinolones, NSAIDs, and cardiovascular medications, should take sun protection measures to prevent photosensitivity reactions 1

Tetracyclines, such as doxycycline, can cause photosensitivity reactions, with doxycycline being more photosensitizing than minocycline 2, 3
Fluoroquinolones, including nalidixic acid, are consistently implicated in phototoxic reactions 1, 4, 5
Thiazide diuretics, such as hydrochlorothiazide, can trigger exaggerated sunburn reactions, dermatitis, and lichenoid eruptions, occurring in 1-2% of patients 1
The American College of Cardiology recommends that patients taking loop diuretics, ACE inhibitors, angiotensin receptor blockers, anti-arrhythmics, calcium channel blockers, and beta-blockers should be aware of the potential for photosensitivity reactions 1
NSAIDs, including naproxen and piroxicam, are consistently implicated in photosensitivity reactions 1, 4, 5

The American Academy of Dermatology recommends that patients taking potentially photosensitive drugs should avoid direct sunlight exposure, particularly around midday, and seek shade when outside 1
Patients should apply broad-spectrum sunscreen with SPF ≥30 to all exposed skin and wear protective clothing covering as much body surface as possible 6
For patients taking tetracyclines, the American Academy of Dermatology recommends avoiding prolonged direct sun exposure, using sunscreens that absorb long-wave UVA radiation, and taking medication in the evening to minimize sun exposure risk 7

Pseudoporphyria can occur with fluoroquinolones, NSAIDs, tetracyclines, and diuretics, more likely after minor trauma on acral sites 4, 5, 8

The National Comprehensive Cancer Network recommends that patients with mild photosensitivity reactions (Grade 1) should continue medication with topical emollients and mild-moderate potency topical corticosteroids 9
For moderate reactions (Grade 2), patients should hold medication, use medium-to-high potency topical corticosteroids, and consider prednisone 0.5-1 mg/kg tapered over 4 weeks 9
For severe reactions (Grade 3), patients should hold medication, consult dermatology, and initiate prednisone 1 mg/kg/day tapered over at least 4 weeks 9

Clonidine is not identified as a photosensitizing agent in guideline or research literature, according to the European Heart Journal 10
Apixaban is associated with bleeding complications, but photosensitivity is not documented, as reported in the European Heart Journal 10
Testosterone supplementation does not pose a photosensitivity risk, as noted in the European Heart Journal 10
Potassium supplementation is not associated with photosensitivity risk, according to the European Heart Journal 10
Topical vitamin D analogues, such as calcipotriene, can cause photosensitivity, as documented in the Journal of the American Academy of Dermatology 11
Oral vitamin D supplementation does not cause photosensitivity reactions, as reported in the Journal of the American Academy of Dermatology 11 and Ophthalmology 12

Amlodipine, olmesartan, and metoprolol are not among the consistently implicated medications for photosensitivity, although they carry theoretical potential, as noted in the European Heart Journal 10
Levetiracetam is not associated with photosensitivity, with the FDA label listing somnolence, asthenia, and behavioral changes as common adverse events, as reported in the European Heart Journal 10

In patients presenting with a rash confined to sun‑exposed sites (e.g., face, neck, dorsal hands, forearms), this distribution pattern supports a diagnosis of HCTZ‑related photosensitivity【13】.

Discontinuation of HCTZ and initiation of a non‑photosensitizing antihypertensive (e.g., ACE inhibitor, ARB, calcium‑channel blocker) is recommended; topical high‑potency corticosteroids applied to the affected areas provide rapid symptomatic relief【13】.
For mild reactions (approximately < 10 % of body surface area), treatment with emollients plus low‑ to moderate‑potency topical corticosteroids is appropriate【13】.
For moderate reactions (approximately 10–30 % of body surface area or when daily activities are limited), a short course of oral prednisone (0.5–1 mg/kg) tapered over four weeks is advised【13】.

Patients should use a broad‑spectrum sunscreen with SPF ≥ 30 on all exposed skin daily, emphasizing formulations with strong UVA protection【14】.
After any phototherapy session, patients must avoid sunlight for at least 24 hours; if driving, they should employ commercially available UVA‑blocking window films【14】.

Amiodarone, hydrochlorothiazide, and certain ACE‑inhibitors/ARBs have been identified as cardiovascular agents that can induce photosensitivity reactions 15.

Clinical guidelines recommend that patients taking photosensitizing medications should apply a broad‑spectrum sunscreen with SPF ≥ 30 to all exposed skin, wear protective clothing covering the maximum body surface area, avoid peak sun hours (approximately 10 AM–4 PM), and seek shade especially around midday 15.

When using topical products such as Itovebi, clinicians should still evaluate any concomitant systemic drugs—particularly cardiovascular, antibiotic, and psychiatric agents—because many of these classes are associated with increased sun‑sensitivity, even though the topical product itself lacks photosensitizing properties 15.